Nayudu Greeshma Sai Sree, Benny Mamkoottathil, Thomas Grace, Adil Khan Maria, Basutkar Roopa Satyanarayan
Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, The Nilgiris, Tamil Nadu, India.
Indian J Community Med. 2023 May-Jun;48(3):390-400. doi: 10.4103/ijcm.ijcm_577_22. Epub 2023 May 30.
The COVID-19 pandemic has caused havoc in the health sector. Inflammatory cytokines play an important role in the disease condition. Existing evidence has provided certain insights into the repurposing of the drugs. This meta-analysis and systematic review aimed to explore the efficacy of the administration of interferon beta-1b (IFN β-1b) and standard care versus only standard care as the therapeutic agent for managing COVID-19 patients who are severely ill. The search was conducted in the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Scopus, and Google Scholar, which were published during the period January 1, 2020, to February 16, 2023. All the included three studies were independently assessed for eligibility. The modified data extraction form of Cochrane were used. The quality of the three included studies was assessed using the Cochrane risk of bias tool. GradePro software was used to summarize the quality grading of the primary outcome measures. The time taken for clinical improvement was (MD: -3.28 days; 95% CI: -5.65, -0.91; value = 0.007) when treated with IFN β-1b. The duration of hospital stays (MD: -2.43 days; 95% CI: -4.45, -0.30; value = 0.03), and need for intensive care unit (ICU) admission (RR: 0.71; 95% CI: 0.52, 0.97; value = 0.03) was statistically significant. Interferon beta-1b is proven to reduce the duration of hospital stay, and the improved clinical status may become a cornerstone of COVID-19 treatment.
新冠疫情给卫生部门带来了严重破坏。炎性细胞因子在该疾病状况中起重要作用。现有证据为药物的重新利用提供了一定见解。这项荟萃分析和系统评价旨在探讨给予β-1b干扰素（IFNβ-1b）和标准护理与仅采用标准护理作为治疗手段来管理重症新冠患者的疗效。检索在以下数据库中进行：Cochrane对照试验中心注册库（CENTRAL）、PubMed、Scopus和谷歌学术，检索范围为2020年1月1日至2023年2月16日期间发表的文献。对所有纳入的三项研究进行独立的资格评估。使用了Cochrane修改后的数据提取表。采用Cochrane偏倚风险工具评估纳入的三项研究的质量。使用GradePro软件总结主要结局指标的质量分级。接受IFNβ-1b治疗时，临床改善所需时间为（MD：-3.28天；95%CI：-5.65，-0.91；P值=0.007）。住院时间（MD：-2.43天；95%CI：-4.45，-0.30；P值=0.03）以及入住重症监护病房（ICU）的需求（RR：0.71；95%CI：0.52，0.97；P值=0.03）具有统计学意义。已证实β-1b干扰素可缩短住院时间，临床状况的改善可能成为新冠治疗的基石。
